Press release Biocartis Holdings Inc.

Recapitalization completed and product portfolio expansion - Seite 2

Biocartis is planning more product launches with its partners this year: Idylla CP-GEP (RUO) and the Idylla ThyroidPrint Assay (RUO). Idylla CP-GEP is developed in partnership with SkylineDx and is based on a powerful proprietary algorithm that combines clinicopathological (CP) factors with gene expression profiling (GEP) information obtained from cutaneous melanoma FFPE⁵ samples. This product enables laboratories to conduct further research in cutaneous melanoma. The Idylla ThyroidPrint Assay is an advanced genomic signature Assay that is developed in collaboration with GeneproDX. This product measures a gene expression signature from FNA⁶ samples and enables laboratories to conduct further research on risk stratification of indeterminate thyroid nodules.

Roger Moody, Chief Executive Officer of Biocartis, commented: “We are very pleased to have the recapitalization behind us. The new funding will, in combination with the significantly lowered cost structure and debt structure, allow Biocartis to invest in expanding its business instead of servicing its debt. Having completed the recapitalization, we have the foundation for a bright future. We are also very excited about our expanding product portfolio. The new oncology tests that we have recently launched should help our growth in 2024 and beyond, as we continue to deliver faster testing solutions to our customers. In addition, we look forward to continuing to expand our product portfolio with tests in the field of cutaneous melanoma and thyroid cancer. Oncologists are looking for faster results to get cancer patients on the right treatment, and our Idylla Platform is the ideal solution to these market needs. We continue to work hard towards the goal for our products to make a difference for cancer patients around the world.”

--- END ---

More information:

Website: www.biocartis.com
e-mail:        [e-mail]

About Biocartis

With its revolutionary and proprietary Idylla Platform, Biocartis aspires to enable personalized medicine for patients around the world through universal access to molecular testing, by making molecular testing actionable, convenient, fast and suitable for any lab. The Idylla Platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster, informed treatment decisions. Idylla's continuously expanding menu of molecular diagnostic tests addresses key unmet clinical needs, with a focus in oncology. This is the fastest growing segment of the molecular diagnostics market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal, lung, breast and liver cancer, as well as for sepsis. More information: www.biocartis.com. Follow us on X (Twitter): @Biocartis_.